Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

858
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
858
Coagulation01:09

Coagulation

7.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

9.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

37
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
37

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asymptomatically growing tumor at the wrist in a middle-aged man.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Expanding Horizons in Thrombosis and Hemostasis: From Molecular Determinants to Real-World and Expert Opinion Evidence.

Hamostaseologie·2026
Same author

Hamostaseologie·2026
Same author

Dental Surgery without Clotting Factor Replacement Therapy during Continued Prophylaxis with Marstacimab, an Inhibitory TFPI Monoclonal Antibody.

Hamostaseologie·2026
Same author

Comparative safety of direct oral anticoagulants and low-molecular-weight heparin in patients with venous thromboembolism and cancer in Europe.

Journal of comparative effectiveness research·2026
Same author

From Case Reports to Cohort Studies: The Many Faces of Clinical Research in Thrombosis and Haemostasis.

Hamostaseologie·2026
Same journal

[Beau's lines: nail disorder reflecting chemotherapy cycles].

Dermatologie (Heidelberg, Germany)·2026
Same journal

Dermatologie (Heidelberg, Germany)·2026
Same journal

[Medical care situation of people with vitiligo : A pilot and feasibility study on guideline-oriented management in German dermatology practices].

Dermatologie (Heidelberg, Germany)·2026
Same journal

[Erythroderma: etiology, diagnosis, and management-an overview].

Dermatologie (Heidelberg, Germany)·2026
Same journal

[New drug therapy approaches in the management of hidradenitis suppurativa].

Dermatologie (Heidelberg, Germany)·2026
Same journal

[Chronic hyperkeratotic plaques on the fingers and axillae in a mother and daughter].

Dermatologie (Heidelberg, Germany)·2026
See all related articles

Related Experiment Video

Updated: Aug 28, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

600

[Cancer-associated coagulation disorders].

Minna Voigtländer1, Florian Langer2

  • 1Zentrum für Onkologie - Universitäres Cancer Center Hamburg (UCCH), II. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.

Dermatologie (Heidelberg, Germany)
|September 14, 2022
PubMed
Summary
This summary is machine-generated.

Managing paraneoplastic coagulation disorders requires careful risk assessment for venous thromboembolism (VTE) prevention and treatment. Treatment strategies for VTE, disseminated intravascular coagulation, and bleeding disorders depend on clinical symptoms and risk stratification.

Keywords:
AnticoagulantsDisseminated intravascular coagulationHemophilia A, acquiredVenous thromboembolismVon Willebrand disease, acquired

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.6K

Related Experiment Videos

Last Updated: Aug 28, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

600
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.6K

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Paraneoplastic coagulation disorders present diagnostic and therapeutic challenges in clinical practice.
  • Prophylactic anticoagulation is standard for surgical and acutely ill cancer patients.
  • Outpatient chemotherapy requires careful risk-benefit evaluation for anticoagulation.

Purpose of the Study:

  • To outline current approaches for diagnosing and treating paraneoplastic coagulation disorders.
  • To emphasize risk stratification for venous thromboembolism (VTE) in cancer patients.
  • To discuss management of bleeding risks associated with malignancy.

Main Methods:

  • Review of established guidelines and clinical practices for VTE prophylaxis and treatment in cancer patients.
  • Application of risk assessment models for anticoagulation decisions during chemotherapy.
  • Algorithmic approaches for bleeding risk stratification in VTE management.
  • Symptom-guided therapeutic measures for disseminated intravascular coagulation.
  • Identification of specific bleeding disorders associated with malignancies.

Main Results:

  • Low-molecular-weight heparin and direct oral factor Xa inhibitors are options for treating cancer-associated VTE.
  • Acquired von Willebrand syndrome can cause severe bleeding in myeloproliferative neoplasms and plasma cell dyscrasias.
  • Malignancy is associated with acquired hemophilia A in 15% of cases.

Conclusions:

  • Effective management of paraneoplastic coagulation disorders necessitates tailored strategies based on individual patient risk.
  • Anticoagulation requires careful consideration of VTE and bleeding risks, especially during outpatient chemotherapy.
  • Specific bleeding tendencies, such as acquired von Willebrand syndrome and acquired hemophilia A, require targeted interventions.